HOME >> BIOLOGY >> NEWS
Promising results in the battle against incurable ALS muscle disease

ALS is an incurable, paralyzing neurodegenerative disorder that strikes 5 persons in every 100,000. The disease commonly affects healthy people in the most active period of their lives - without warning or previous family history. Researchers from VIB (the Flanders Interuniversity Institute for Biotechnology), under the direction of Prof. Peter Carmeliet (Catholic University of Leuven), have previously shown the importance of the VEGF protein in this disease. Now, new research from this group shows that rats with a severe form of ALS live longer following the administration of the VEGF protein as a remedy. These results open up new possibilities for the use of VEGF in the treatment of ALS.

An incurable disease of the muscles

Amyotrophic Lateral Sclerosis (ALS) can strike anyone. The Chinese leader Mao Tse Tung, Russian composer Dimitri Sjostakowitz, the legendary New York Yankee baseball player Lou Gehrig, and astro-physicist Stephen Hawkins have all been afflicted with ALS. In addition, an unusually large number of Italian professional soccer players, airline pilots, and soldiers from the Golf War have been stricken by this fatal disease. About half of them have died within three years - some even in the first year - and usually as a consequence of asphyxiation, while still 'in full possession of their faculties'.

In ALS, the patient's nerve bundles that extend to the muscles deteriorate. This causes the patient to lose control over his/her muscles, growing progressively paralyzed - but remaining (disconcertingly) fully alert mentally. The originating mechanism of this deadly disease of deterioration - which has an enormous medico-social impact - remains obscure. At present, the disease is totally untreatable - causing many ALS patients to choose euthanasia, a very controversial solution. However, previous genetic research by Peter Carmeliet and his team at the Catholic University of Leuven has led to the surprising discovery tha
'"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
32-9-244-6611
VIB, Flanders Interuniversity Institute of Biotechnology
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Promising protein may prevent eye damage in premature babies
2. Tailored treatments: Promising designer drug provides new insight into cancer biology
3. Promising antiobesity drug fails to produce clinically meaningful weight loss
4. Promising preclinical results with live attenuated H5N1 vaccines
5. Promising new research on hereditary diseases
6. Promising cell protein may play role in infection and dry eye
7. Promising anti-TB compound finally can be synthesized with ease
8. Promising new preventative treatment option for population of men at high risk of prostate cancer
9. Cooperative science program yields results
10. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
11. Smelling for first time results from knowing abnormalities in congenital loss of smell

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/5/2019)... ... November 05, 2019 , ... Dr. Lauren Kopp ... dentistry to Seattle, WA, including porcelain veneers , smile makeovers, dental implants, ... University of Washington, Dr. Kopp is passionate about serving her Seattle community with ...
(Date:11/2/2019)... ... 2019 , ... Stay on top of current hot topics through free webinars ... webinars is free, so be sure to register today to save your place! Participate ... to see our upcoming webinars: , CLINICAL OPERATIONS , November 14 – Leveraging Technology ...
(Date:10/30/2019)... ... October 30, 2019 , ... The ... Knowledge Center in which participants will learn about precision agriculture tools used to ... these technologies. , Participants will have the opportunity to visit Virginia Tech’s ...
Breaking Biology News(10 mins):
(Date:11/9/2019)... , ... November 08, 2019 ... ... artificial intelligence (AI)-powered technology for use in pathology research, today announced the ... biopsy samples from patients enrolled in the phase 3 selonsertib studies (STELLAR). ...
(Date:11/6/2019)... , ... November 06, 2019 , ... ... through off-the-record collaboration and dialogue, today announces its East/West CEO conference ... in San Francisco. , Kicking off the week of the J.P. ...
(Date:11/5/2019)... ... 2019 , ... Focal Healthcare , an innovator of ... Bx 2.0 prostate fusion biopsy solution. By combining information from multiparametric MRI (mpMRI) ... urologists across Europe the ability to perform targeted transrectal and transperineal prostate biopsies. ...
(Date:11/2/2019)... ... October 31, 2019 , ... A ... communicating with each other: study managers, principal investigators, supply chain managers, manufacturers, IRT, ... is not informed of the latest data, potentially leading to patient risk. , ...
Breaking Biology Technology:
Cached News: